Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis and HIV news

Show

From To
Presidio Pharmaceuticals Announces Collaboration with Boehringer Ingelheim

The Parties to Initiate a Phase IIa Trial of an All-Oral Combination of Presidio’s HCV NS5A inhibitor (PPI-668) with Faldaprevir (BI201335) and BI207127 for the Treatment of Patients with Hepatitis C.

Published
13 March 2013
From
Presidio press release
Expanding High Risk Population Drives European Hepatitis B and C Diagnostics Market

New analysis from Frost & Sullivan, Analysis of the European Hepatitis B and C Diagnostics Market, estimates revenues of the hepatitis B diagnostics to grow from $165.9 million in 2012 to $260.2 million in 2019 and hepatitis C diagnostics market to grow from $3,140.8 million in 2012 to $4,940.9 million in 2019, respectively.

Published
13 March 2013
From
PR Newswire (press release)
Adding telaprevir improves acute hepatitis C treatment for HIV-positive men

Adding telaprevir (Incivo or Incivek) to pegylated interferon and ribavirin shortens the duration of treatment and increases the likelihood of a cure for HIV-positive men with acute

Published
12 March 2013
By
Liz Highleyman
Simeprevir & sofosbuvir demonstrates good early cure rate with or without ribavirin

An all-oral combination of simeprevir plus sofosbuvir, with or without ribavirin, led to an early cure for most hard-to-treat prior null responders with genotype 1 hepatitis C

Published
12 March 2013
By
Liz Highleyman
NY aims to prevent unsafe injections

The Safe Injection Practices Coalition, a group of healthcare-related organizations including the CDC indicated since 2001, more than 150,000 patients in the U.S. were told they may have been exposed to hepatitis B, hepatitis C, or human immunodeficiency virus because providers followed unsafe injection procedures.

Published
12 March 2013
From
UPI.com
Telaprevir shows promise in black patients with genotype 1 HCV

Preliminary data presented here at the 2013 Conference on Retroviruses and Opportunistic Infections show that combination telaprevir treatment may be effective in black null responder patients with chronic genotype 1 hepatitis C.

Published
12 March 2013
From
Healio
Faldaprevir ups interferon response in HIV/HCV co-infection

Adding the hepatitis C virus (HCV) protease inhibitor faldaprevir (formerly BI 201335) to pegylated interferon and ribavirin led to a higher early response rate and the potential

Published
11 March 2013
By
Liz Highleyman
Simeprevir pushes HCV cure rate above 75% for HIV/HCV co-infection

Adding the new hepatitis C virus (HCV) protease inhibitor simeprevir (formerly TMC435) to pegylated interferon and ribavirin cures about three-quarters of HIV/HCV co-infected people, most of them with

Published
11 March 2013
By
Liz Highleyman
England: lack of planning for hepatitis C services risks future chaos and huge healthcare costs

New report finds that local authorities and NHS organisations need to prioritise hepatitis C now or risk missing a rare opportunity.

Published
11 March 2013
From
Hepatitis C Trust press release
Pfizer stops developing hepatitis C drug

Pfizer Inc. has stopped development of an experimental hepatitis C drug, bowing out of a hotly contested industry race to introduce the next generation of treatments for the infectious liver disease.

Published
10 March 2013
From
EATG

Filter by country